Discover investment opportunities in Best Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Psychedelic Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Psychedelic Stocks using our Smart AI Filter.
8 stocks found for "Best Psychedelic Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.17 Risk measure | ±100.0% Price volatility | -4.1 Valuation | 0.00% Annual yield | |||
1.02 Risk measure | ±100.0% Price volatility | -0.3 Valuation | 0.00% Annual yield | |||
0.82 Risk measure | ±100.0% Price volatility | -13.0 Valuation | 0.00% Annual yield | |||
0.12 Risk measure | ±100.0% Price volatility | — Valuation | 0.00% Annual yield | |||
0.49 Risk measure | ±66.7% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
0.91 Risk measure | ±49.4% Price volatility | 19.1 Valuation | 2.86% Annual yield | |||
1.28 Risk measure | ±88.5% Price volatility | -5.2 Valuation | 0.00% Annual yield | |||
2.23 Risk measure | ±99.6% Price volatility | 441.5 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read moreLRN's stock slides 9% on a key contract loss, but 20% enrollment growth and strong fundamentals may hint at long-term upside.
Read moreThe consensus price target hints at an 831.4% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read moreThe average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read moreThe mean of analysts' price targets for Mind Medicine MindMed (MNMD) points to a 237.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read moreOn Wednesday, Relmada Therapeutics, Inc. RLMD announced a preplanned interim analysis of the Reliance II Phase 3 study.
Read more